In recent trading session, CRISPR Therapeutics AG (NASDAQ:CRSP) saw 1,312,564 shares changing hands at last check today with its beta currently measuring 2.31. Company’s recent per share price level of $153.89 trading at -$5.16 or -3.24% at last check today assigns it a market valuation of $11.56 Billion. That most recent trading price of CRSP’s stock is at a discount of -43.09% from its 52-week high price of $220.2 and is indicating a premium of 79.01% from its 52-week low price of $32.3. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.39 Million shares which gives us an average trading volume of 2.05 Million if we extend that period to 3-months.
For CRISPR Therapeutics AG (CRSP), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.4. Splitting up the data highlights that, out of 19 analysts covering the stock, 2 rated the stock as a Sell while none recommended an Overweight rating for the stock. 7 suggested the stock as a Hold whereas 10 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$1.27 in the current quarter.
In the face of being in the red today for losing -3.24%, in the last five days CRSP remained trading in the green while hitting it’s week-highest on Tuesday, Feb 09 when the stock touched $175.44 price level, adding 11.74% to its value on the day. CRISPR Therapeutics AG’s shares saw a change of 1.14% in year-to-date performance and have moved -8.27% in past 5-day. CRISPR Therapeutics AG (NASDAQ:CRSP) showed a performance of -18.65% in past 30-days. Number of shares sold short was 2.95 Million shares which calculate 1.44 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $146.56 to the stock, which implies targetted prices is already lagging behind -4.76% to its recent value today. Analysts have been projecting $45 as a low price target for the stock while placing it at a high target of $210. It follows that stock’s price at last check today has to jump +36.46% in reaching the projected high whereas dropping to the targeted low would mean a loss of -70.76% for stock’s latest value.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Statistics highlight that CRISPR Therapeutics AG is scoring comparatively lower than the scores of other players of the relevant industry. The company added +74.19% of value to its shares in past 6 months, showing an annual growth rate of -524.79% while that of industry is 14.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to decline by -349% in the current quarter and calculating -16.5% decline in the next quarter. This year revenue growth is estimated to drop -99.2% from the last financial year’s standing.
14 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.32 Million for the same. And 10 analysts are in estimates of company making revenue of $1.66 Million in the next quarter that will end on March 01, 2021. Company posted $77.02 Million and $3.04 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -97% while estimating it to be -45.4% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 54% during past 5 years. In 2021, company’s earnings growth rate is likely to be around 134.1% while estimates for its earnings growth in next 5 years are of 0%
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders are in possession of 13.71% of company’s total shares while institution are holding 68.49% percent of that, with stock having share float percentage of 79.38%. Investors also watch the number of corporate investors in a company very closely, which is 405 institutions for CRISPR Therapeutics AG that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at CRSP for having 8.46 Million shares of worth $707.37 Million. And as of September 29, 2020, it was holding 11.97% of the company’s outstanding shares.
The second largest institutional holder is Capital International Investors, which was holding about 7.39 Million shares on September 29, 2020. The number of shares represents firm’s hold over 10.47% of outstanding shares, having a total worth of $618.46 Million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc are the top two Mutual Funds which own company’s shares. As of December 30, 2020, the former fund manager was holding 6384590 shares of worth $977.54 Million or 9.04% of the total outstanding shares. The later fund manager was in possession of 3.22 Million shares on December 30, 2020, making its stake of worth around $492.76 Million in the company or a holder of 4.56% of company’s stock.